Latest Insider Transactions at Agios Pharmaceuticals, Inc. (AGIO)
This section provides a real-time view of insider transactions for Agios Pharmaceuticals, Inc. (AGIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AGIOS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AGIOS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 03
2021
|
Jonathan Biller Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,753
+25.71%
|
-
|
|
Dec 02
2021
|
Sarah Gheuens Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
248
-5.77%
|
$8,680
$35.0 P/Share
|
|
Dec 02
2021
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
834
+16.26%
|
-
|
|
Jun 21
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,777
-100.0%
|
$108,397
$61.61 P/Share
|
|
Jun 21
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+50.0%
|
$90,627
$51.51 P/Share
|
|
Jun 18
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
48,493
-75.79%
|
$2,909,580
$60.11 P/Share
|
|
Jun 18
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
48,493
+25.97%
|
$2,182,185
$45.08 P/Share
|
|
Jun 17
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,502
-13.91%
|
$150,120
$60.02 P/Share
|
|
Jun 17
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,502
+12.21%
|
$97,578
$39.76 P/Share
|
|
Jun 10
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,853
-57.38%
|
$1,251,180
$60.06 P/Share
|
|
Jun 10
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,853
+36.46%
|
$813,267
$39.76 P/Share
|
|
Jun 09
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,149
-31.58%
|
$428,940
$60.16 P/Share
|
|
Jun 09
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,149
+24.0%
|
$278,811
$39.76 P/Share
|
|
Jun 08
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,675
-30.12%
|
$400,500
$60.07 P/Share
|
|
Jun 08
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,675
+23.15%
|
$260,325
$39.76 P/Share
|
|
Jun 07
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,268
-21.6%
|
$256,080
$60.04 P/Share
|
|
Jun 07
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,268
+17.77%
|
$166,452
$39.76 P/Share
|
|
May 28
2021
|
Maykin Ho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+25.35%
|
-
|
|
May 28
2021
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+1.45%
|
-
|
|
May 28
2021
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+23.35%
|
-
|
|
May 28
2021
|
Paul J Clancy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+25.35%
|
-
|
|
May 28
2021
|
Kaye I Foster Cheek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+19.05%
|
-
|
|
May 28
2021
|
John Maraganore Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+5.6%
|
-
|
|
May 28
2021
|
Ian T Clark Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+25.35%
|
-
|
|
May 14
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,462
-32.44%
|
$190,410
$55.41 P/Share
|
|
Apr 20
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,401
-48.18%
|
$792,055
$55.11 P/Share
|
|
Apr 20
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,401
+18.41%
|
$532,837
$37.46 P/Share
|
|
Apr 19
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,210
-17.17%
|
$176,550
$55.16 P/Share
|
|
Apr 19
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,210
+14.65%
|
$112,350
$35.16 P/Share
|
|
Apr 16
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,118
-100.0%
|
$61,490
$55.89 P/Share
|
|
Apr 15
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
991
-46.99%
|
$53,514
$54.0 P/Share
|
|
Mar 05
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
500
-4.48%
|
$24,000
$48.58 P/Share
|
|
Mar 01
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,200
-16.45%
|
$103,400
$47.99 P/Share
|
|
Feb 24
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
986
-6.01%
|
-
|
|
Feb 22
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+16.9%
|
-
|
|
Feb 22
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
199
-9.98%
|
-
|
|
Feb 22
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
692
+25.76%
|
-
|
|
Feb 22
2021
|
David P Schenkein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
821
-0.72%
|
-
|
|
Feb 22
2021
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,774
+2.39%
|
-
|
|
Feb 22
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-1.62%
|
-
|
|
Feb 22
2021
|
Darrin Miles Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
725
+5.18%
|
-
|
|
Feb 16
2021
|
David P Schenkein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,540
-2.24%
|
-
|
|
Feb 16
2021
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,125
+6.7%
|
-
|
|
Feb 16
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
561
-30.11%
|
-
|
|
Feb 16
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
790
+29.78%
|
-
|
|
Feb 16
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,069
-13.67%
|
-
|
|
Feb 16
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+15.38%
|
-
|
|
Feb 16
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,916
-18.86%
|
-
|
|
Feb 16
2021
|
Darrin Miles Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
922
+5.63%
|
-
|
|
Feb 14
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
889
+45.31%
|
-
|